-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
-
UCLA's Scooter Jackson named Week 11 Lott IMPACT Trophy Player of the Week
-
Paris Hilton Guides Loti as Chief Advocacy Officer to Put Digital Identity Protection in Everyone's Hands
-
Ondas and Aston Martin Aramco Formula One Team Launch Multi-Year Partnership Built for "Speed to Decision"
-
Who Does the Best Testosterone Replacement Therapy in Las Vegas?
-
CMP 2026-2027 Nonprofit Leadership Pulse Check
-
Nexteer's HMDD Wins Innovation Awards from PACE Pilot, CES and AutoTech Breakthrough
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
More Than Keyboards: Epomaker Brings Its Gaming World to G-STAR 2026
Moderna Covid vaccine gets full US approval
The US Food and Drug Administration (FDA) announced Monday that it has granted full approval to Moderna's Covid-19 "Spikevax" vaccine, which had previously received an emergency use authorization in the United States.
"The public can be assured that Spikevax meets the FDA's high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States," acting FDA commissioner Janet Woodcock said in a statement.
"The FDA's approval of Spikevax is a significant step in the fight against the Covid-19 pandemic, marking the second vaccine approved to prevent Covid-19," Woodcock said.
The full approval of the Moderna vaccine is for individuals aged 18 or older.
A Pfizer vaccine for individuals aged 16 or older received full FDA approval at the end of August.
Woodcock said she hoped FDA approval of the Moderna vaccine "may instill additional confidence in making the decision to get vaccinated."
Moderna CEO Stephane Bancel called the FDA move a "momentous milestone" for the company.
"Our Covid-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from Covid-19 infection, hospitalization and death," Bancel said in a statement.
The Moderna vaccine received an emergency use authorization in December 2020.
The full approval from the FDA concerns the first two doses of the Moderna vaccine. A booster dose remains under an emergency use authorization.
The FDA said clinical trials to determine the effectiveness of Spikevax included 14,287 vaccine recipients and 14,164 placebo recipients.
The most common side effects by clinical trial participants were pain at the injection site, fatigue, headaches, muscle or joint pain, chills, nausea or vomiting and swollen lymph nodes, the FDA said.
It said there was an increased risk in men aged 18 to 24 of myocarditis -- inflammation of the heart muscle -- and pericarditis -- inflammation of tissue surrounding the heart -- following vaccination with the second dose.
But, the FDA said, it has determined that the "benefits of the vaccine outweigh the risk of myocarditis and pericarditis in individuals 18 years of age and older."
M.King--AT